CLN-049

Treatment Description

CLN-049 is a T cell engaging bispecific antibody that targets FTL3 on cancer cells, and CD3 on T cells. It is being studied for use in different cancers.

Participating Centers

There are 7 centers running trials with this treatment. Enter a location below to find the closest center.